Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.117
G. Fazzina, M. Bellero, D. Marino, S. Terzolo, E. Sperti, C. Zichi, Fulvia Codegone, C. Paratore, Giovanna Ciriolo, M. Maio, A. Gascó
{"title":"4CPS-285 Multidisciplinary oral therapy outpatient clinic: an Italian single centre experience","authors":"G. Fazzina, M. Bellero, D. Marino, S. Terzolo, E. Sperti, C. Zichi, Fulvia Codegone, C. Paratore, Giovanna Ciriolo, M. Maio, A. Gascó","doi":"10.1136/EJHPHARM-2021-EAHPCONF.117","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.117","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80878049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.297
L. Cantarelli, F. G. Nicolás, J. G. Garcia, Gj Nazco Casariego
Background and importance Tocilizumab (TCZ) has been proposed to mitigate the cytokine storm syndrome associated with SARS-CoV-2. However, acute administration of this drug has been shown to cause serious adverse effects at the level of the liver, including acute liver failure. Aim and objectives To evaluate the liver toxicity profile associated with the acute use of TCZ in patients with SARS-CoV-2 infection. Material and methods A retrospective single centre study, lasting 2 months (March to April 2020), was conducted in all patients with a clinical suspicion/diagnosis confirmed of SARS-CoV-2 infection and who had received treatment with TCZ. The following variables were collected: age, sex, posology scheme of TCZ, admission to the intensive care unit (ICU), need for orotracheal intubation (OTI) and death during the hospital stay. The hepatic profile was analysed for levels of hepatic transaminases (GOT/AST and GPT/ALT) and total bilirubin (TOT BL) pre and post completion of treatment with TCZ. Alteration of liver parameters was classified as mild (1–3 × upper limit of normality (UPN)), moderate (3–5 × UPN) and severe (≥5 × UPN). Results During the study period, 44 patients with SARS-CoV-2 infection were treated with TCZ (65.9% men (n=29); mean age 62.3 years (31–82)). The posology scheme of TCZ used was the following: single dose (68.2%, n=30), double dose (18.2%, n=8) and triple dose (11.6%, n=6). Two patients (4.5%) received a 50% reduced dose because of previous liver failure. During admission, 56.8% (n=25) of patients required a stay in the ICU. 36.4% (n=16) needed OTI. 9.1% (n=4) died during admission. Liver profile analysis showed that 72.7% of patients (n=32) presented with normal levels of GPT/ALT and GOT/AST before treatment. 59.1% (n=26) presented with normal levels of BL TOT and 4.5% (n=2) had high levels. In 34.1% (n=15) there were no data. After treatment with TCZ, 86.3% (n=38) developed hepatotoxicity. Elevation of GPT/ALT was observed: mild (42.1%), moderate (28.9%) and severe (28.9%); elevation of GOT/AST: mild (44.7%), moderate (31.6%) and severe (13.2%). 42.9% (n=12) presented with high levels of BL TOT after receiving TCZ. Conclusion and relevance The study showed how a high proportion of patients with SARS-CoV-2 infection developed severe liver toxicity after the use of the drug. However, future studies will be needed to clarify the involvement of SARS-CoV-2 itself in the development of hepatotoxicity. References and/or acknowledgements Conflict of interest No conflict of interest
{"title":"5PSQ-178 Hepatotoxicity associated with acute tocilizumab treatment in patients with SARS-CoV-2 infection","authors":"L. Cantarelli, F. G. Nicolás, J. G. Garcia, Gj Nazco Casariego","doi":"10.1136/EJHPHARM-2021-EAHPCONF.297","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.297","url":null,"abstract":"Background and importance Tocilizumab (TCZ) has been proposed to mitigate the cytokine storm syndrome associated with SARS-CoV-2. However, acute administration of this drug has been shown to cause serious adverse effects at the level of the liver, including acute liver failure. Aim and objectives To evaluate the liver toxicity profile associated with the acute use of TCZ in patients with SARS-CoV-2 infection. Material and methods A retrospective single centre study, lasting 2 months (March to April 2020), was conducted in all patients with a clinical suspicion/diagnosis confirmed of SARS-CoV-2 infection and who had received treatment with TCZ. The following variables were collected: age, sex, posology scheme of TCZ, admission to the intensive care unit (ICU), need for orotracheal intubation (OTI) and death during the hospital stay. The hepatic profile was analysed for levels of hepatic transaminases (GOT/AST and GPT/ALT) and total bilirubin (TOT BL) pre and post completion of treatment with TCZ. Alteration of liver parameters was classified as mild (1–3 × upper limit of normality (UPN)), moderate (3–5 × UPN) and severe (≥5 × UPN). Results During the study period, 44 patients with SARS-CoV-2 infection were treated with TCZ (65.9% men (n=29); mean age 62.3 years (31–82)). The posology scheme of TCZ used was the following: single dose (68.2%, n=30), double dose (18.2%, n=8) and triple dose (11.6%, n=6). Two patients (4.5%) received a 50% reduced dose because of previous liver failure. During admission, 56.8% (n=25) of patients required a stay in the ICU. 36.4% (n=16) needed OTI. 9.1% (n=4) died during admission. Liver profile analysis showed that 72.7% of patients (n=32) presented with normal levels of GPT/ALT and GOT/AST before treatment. 59.1% (n=26) presented with normal levels of BL TOT and 4.5% (n=2) had high levels. In 34.1% (n=15) there were no data. After treatment with TCZ, 86.3% (n=38) developed hepatotoxicity. Elevation of GPT/ALT was observed: mild (42.1%), moderate (28.9%) and severe (28.9%); elevation of GOT/AST: mild (44.7%), moderate (31.6%) and severe (13.2%). 42.9% (n=12) presented with high levels of BL TOT after receiving TCZ. Conclusion and relevance The study showed how a high proportion of patients with SARS-CoV-2 infection developed severe liver toxicity after the use of the drug. However, future studies will be needed to clarify the involvement of SARS-CoV-2 itself in the development of hepatotoxicity. References and/or acknowledgements Conflict of interest No conflict of interest","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79868205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.103
C. Cid, R. García, E. Cano, Y. López, N. Gomez, J. M. Pozo
{"title":"4CPS-271 Evaluation of the efficacy of anti-PD-L1 immunotherapy in non-microcritical lung cancer in clinical practice","authors":"C. Cid, R. García, E. Cano, Y. López, N. Gomez, J. M. Pozo","doi":"10.1136/EJHPHARM-2021-EAHPCONF.103","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.103","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80013282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.86
A. Francesco, M. Zito, S. Esposito, C. Monopoli, Naturale, M. D. Fina
{"title":"4CPS-254 A retrospective study of antimicrobial stewardship in a university hospital","authors":"A. Francesco, M. Zito, S. Esposito, C. Monopoli, Naturale, M. D. Fina","doi":"10.1136/EJHPHARM-2021-EAHPCONF.86","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.86","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88650725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.282
JM Vinuesa Hernando, M. Z. Berjaga, R. Piquer, R. F. Molina, P. Rivas, M. Gimeno, I. Martínez, M. López
{"title":"5PSQ-163 Incidence of neutropenia and effectiveness of palbociclib in clinical practice in metastatic breast cancer after 4 years of use","authors":"JM Vinuesa Hernando, M. Z. Berjaga, R. Piquer, R. F. Molina, P. Rivas, M. Gimeno, I. Martínez, M. López","doi":"10.1136/EJHPHARM-2021-EAHPCONF.282","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.282","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88655428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.259
P. Sorice, S. Corridoni, L. Armillei, F. Gasbarri, G. Florio, S. Pizzica, C. Cinalli, G. D. Carlo, A. Romagnoli, L. Auriemma, A. Costantini
{"title":"5PSQ-140 Unit dose system: model of implementation of the antimicrobial stewardship","authors":"P. Sorice, S. Corridoni, L. Armillei, F. Gasbarri, G. Florio, S. Pizzica, C. Cinalli, G. D. Carlo, A. Romagnoli, L. Auriemma, A. Costantini","doi":"10.1136/EJHPHARM-2021-EAHPCONF.259","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.259","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86664297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.326
P. Pacheco-López, C. F. Zamora, Má Carvajal-Sánchez, S. Clavijos-Bautista, MA Meroño-Saura, J. Ibañez-Caturla, P. Torrano-Belmonte, L. Fructuoso-González, Nájera-Pérez
{"title":"5PSQ-207 Analysis of the medicines under additional monitoring authorised in the European Union from 2017 to 2019","authors":"P. Pacheco-López, C. F. Zamora, Má Carvajal-Sánchez, S. Clavijos-Bautista, MA Meroño-Saura, J. Ibañez-Caturla, P. Torrano-Belmonte, L. Fructuoso-González, Nájera-Pérez","doi":"10.1136/EJHPHARM-2021-EAHPCONF.326","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.326","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90188200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.38
E. Kytö, P. Suonvieri, G. Moroni, M. Federici
{"title":"3PC-063 Performance qualification of robotic system for cytotoxic drug preparation in a fully GMP compliant hospital pharmacy","authors":"E. Kytö, P. Suonvieri, G. Moroni, M. Federici","doi":"10.1136/EJHPHARM-2021-EAHPCONF.38","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.38","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80709343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.61
M. Solana, A. G. Sánchez, Michael Rodriguez, M. Magaña, B. Goitia
{"title":"4CPS-229 Analysis of clinical pharmacist interventions in the heart failure day hospital","authors":"M. Solana, A. G. Sánchez, Michael Rodriguez, M. Magaña, B. Goitia","doi":"10.1136/EJHPHARM-2021-EAHPCONF.61","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.61","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79660617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.138
A. S. Ruíz, R. García, C. Cid
{"title":"4CPS-306 Darolutamide, enzalutamide and apalutamide: place in therapeutics of castration resistant non-metastatic prostate cancer","authors":"A. S. Ruíz, R. García, C. Cid","doi":"10.1136/EJHPHARM-2021-EAHPCONF.138","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.138","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81316798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：